文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

慢性粒单核细胞白血病白血病起始干细胞表型特征

Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
PubMed 文献 · Leukemia · 2021-03-30

该研究在慢性粒单核细胞白血病(CMML)中鉴定白血病干细胞(LSC)位于恶性克隆的CD34+/CD38-组分,该组分可在NSGS小鼠中重建CMML,而CD34+/CD38+祖细胞或CD34-单核细胞不能。CMML LSC恒定表达CD33、CD117、CD123和CD133,部分患者表达CD52、IL-1RAP和/或CLL-1,不表达CD25或CD26;进展为继发性急性髓系白血病(sAML)时LSC表达CD25及高水平CD114、CD123和IL-1RAP。体外预孵育吉妥珠单抗奥唑米星或维奈克拉可降低CMML LSC生长并损害NSGS小鼠植入。

要点

  • CMML LSC位于CD34+/CD38-组分,可重建CMML。
  • CMML LSC恒定表达CD33、CD117、CD123、CD133。
  • 进展为sAML时LSC表达CD25及高水平CD114、CD123、IL-1RAP。

核心结论

  • CMML LSC为CD34+/CD38-细胞,表达特定表面标志与靶抗原,进展为sAML时获得或上调CD25、CD114、CD123等细胞因子受体。

研究设计与样本

  • 实验研究:从CMML患者恶性克隆中分选CD34+/CD38-、CD34+/CD38+及CD34-单核细胞,进行NSGS小鼠移植及表型分析。

主要发现

  • CD34+/CD38-细胞可在NSGS小鼠中重建CMML,而CD34+/CD38+祖细胞或CD34-单核细胞未产生CMML。
  • CMML LSC恒定表达CD33、CD117、CD123和CD133,部分患者表达CD52、IL-1RAP和/或CLL-1,不表达CD25或CD26。
  • sAML following CMML的LSC表达CD25及高水平CD114、CD123和IL-1RAP。
  • LSC表型与CMML变异型、突变谱或临床病程间未发现相关性。
  • 预孵育吉妥珠单抗奥唑米星或维奈克拉降低CMML LSC生长并损害NSGS小鼠植入。

临床怎么用

  • 可利用CD34+/CD38-及CD33、CD117、CD123、CD133等标志富集CMML LSC以开发清除LSC的治疗。
  • 吉妥珠单抗奥唑米星或维奈克拉在实验中可降低CMML LSC生长与植入,提示潜在靶向策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myelomonocytic leukemia (CMML) is a stem cell-derived neoplasm characterized by dysplasia, uncontrolled expansion of monocytes, and substantial risk to transform to secondary acute myeloid leukemia (sAML). So far, little is known about CMML-initiating cells. We found that leukemic stem cells (LSC) in CMML reside in a CD34+/CD38- fraction of the malignant clone. Whereas CD34+/CD38- cells engrafted NSGS mice with overt CMML, no CMML was produced by CD34+/CD38+ progenitors or the bulk of CD34- monocytes. CMML LSC invariably expressed CD33, CD117, CD123 and CD133. In a subset of patients, CMML LSC also displayed CD52, IL-1RAP and/or CLL-1. CMML LSC did not express CD25 or CD26. However, in sAML following CMML, the LSC also expressed CD25 and high levels of CD114, CD123 and IL-1RAP. No correlations between LSC phenotypes, CMML-variant, mutation-profiles, or clinical course were identified. Pre-incubation of CMML LSC with gemtuzumab-ozogamicin or venetoclax resulted in decreased growth and impaired engraftment in NSGS mice. Together, CMML LSC are CD34+/CD38- cells that express a distinct profile of surface markers and target-antigens. During progression to sAML, LSC acquire or upregulate certain cytokine receptors, including CD25, CD114 and CD123. Characterization of CMML LSC should facilitate their enrichment and the development of LSC-eradicating therapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Eisenwort G, Sadovnik I, Keller A, et al. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia. 2021. PMID: 33785864. doi:10.1038/s41375-021-01227-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。